Dermatology News

A child in North Dakota acquired cutaneous leishmaniasis from a different etiologic species than the Leishmania mexicana species that has been documented in the 10 cases of the disease in the south-central United States, according to a case report published in Clinical Infectious Diseases.

Healio.com/Dermatology reports on five topical products used for the treatment of common skin infections.

The FDA today announced the approval of dalbavancin for adults with serious skin infections caused by certain gram-positive organisms.

Nafcillin was associated with more frequent premature antimicrobial discontinuation and with more drug-emergent events when used in patients with methicillin-susceptible Staphylococcus aureus, according to researchers from Massachusetts General Hospital.

Data from multiple studies released during the 2014 European Congress of Clinical Microbiology and Infectious Diseases demonstrate the in vitro potency of telavancin and its efficacy in patients with complicated skin and skin structure infections, including MRSA.

Patients with grade 3 widespread morbilliform eruption associated with telaprevir can continue their triple therapy as long as they are closely monitored, according to researchers from Massachusetts General Hospital.

In patients with severe cutaneous adverse reactions related to systemic antibiotics, the presence of underlying comorbidities may contribute to increased mortality, according to recent findings from Taiwan.

Timely testing and diagnosis may be crucial to effectively treat bacterial infections of the skin and subcutaneous tissues, according to data presented at the 2014 American Academy of Dermatology Annual Meeting.

At the beginning of the AIDS epidemic, Kaposi’s sarcoma was identified as a major sign of HIV infection. In the movie Philadelphia, Tom Hanks’ character was thin, drawn, with dark lesions that he tried to hide. HIV and Kaposi’s sarcoma became synonymous with death, becoming known as the “gay man’s cancer.” Throughout the first years of the AIDS era, cutaneous manifestations of the disease were one of the major facets of the disease.

The FDA Anti-Infective Drugs Advisory Committee has voted unanimously that dalbavancin has demonstrated substantial effectiveness and safety for the treatment of acute bacterial skin and skin structure infections caused by certain gram-positive organisms, including staphylococci and streptococci.